Company coronavirus news summary – WHO updates guidance on corticosteroids and Covid-19 – EMA reviews Taw Pharma’s application for dexmethasone

3 September 2020 (Last Updated September 3rd, 2020 09:19)

3 September 2020 

The European Medicines Agency (EMA) is reviewing an application of Dexamethasone Taw, submitted by Taw Pharma, as a potential treatment for hospitalised adults with Covid-19. EMA said that its human medicines committee, CHMP, will assess the benefits and risks of the drug candidate within the shortest possible timeframe.

An analysis of seven international clinical trials showed that treatment with corticosteroid drugs cuts the risk of death by 20% in critically ill Covid-19 patients. Based on these findings, the World Health Organization (WHO) has updated its treatment guidance, recommending the use of steroids for severe and critical Covid-19.

Russia has granted approval for a Phase III clinical trial of China-based CanSino Biologics' Covid-19 vaccine candidate, developed in alliance with the Chinese military’s research arm. The trial of the Ad5-nCoV vaccine candidate has been launched in Moscow. CanSino will work with Petrovax Pharm to conduct the trials in Russia.

Parnell Pharmaceuticals has developed a topical nasal spray, called Nomovid, as prophylaxis against Covid-19. The spray is based upon a substance licensed by the company from New Mexico Tech University to treat drug-resistant bacteria and fungi. Studies showed the substance to be more than 99.9% effective in-vitro against the SARS-CoV-2 virus. Parnell is seeking emergency use authorisation for the medication in the US.